NextCure Provides Business Update

Core Viewpoint - NextCure, Inc. is advancing its clinical-stage biopharmaceutical programs focused on developing novel therapies for cancer treatment, specifically through its antibody drug conjugate (ADC) programs, SIM0505 and LNCB74, while also reporting a preliminary cash position for year-end 2025 [1]. Group 1: ADC Programs - SIM0505 is a novel ADC targeting cadherin-6 (CDH6), which is overexpressed in various cancers and has limited expression in healthy tissues. It utilizes a proprietary topoisomerase 1 inhibitor (TOPOi) payload designed for broad anti-tumor activity and fast systemic clearance [2][5]. - LNCB74 is another ADC directed at B7-H4, also overexpressed in several cancers with limited healthy tissue expression. It features a proprietary tumor-selective cleavable linker and a tubulin inhibitor payload, monomethyl auristatin E (MMAE) [3][6]. Group 2: Clinical Trials and Data Updates - Phase 1 dose escalation data for SIM0505 is expected to be presented in Q2 2026, focusing on advanced solid tumors, particularly gynecological cancers and platinum-resistant ovarian cancer [9]. - The ongoing Phase 1 study for LNCB74 has expanded into higher dose cohorts, prioritizing patients with high B7-H4 expression in breast and gynecological cancers, and now includes adenoid cystic carcinoma type 1 [9]. Group 3: Financial Position - As of December 31, 2025, NextCure reported preliminary cash, cash equivalents, and marketable securities of approximately $41.8 million, which is expected to fund planned operating expenses and capital expenditures into the first half of 2027 [9].